CASI Pharmaceuticals reported an initial statement of beneficial ownership by Wei-Wu He, who is listed as a director and 10% owner. He reported direct beneficial ownership of 1,910,550 ordinary shares. He also reported indirect beneficial ownership of 1,834,985 ordinary shares. He reported options to buy 540,000 ordinary shares at an exercise price of USD 1.93.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CASI Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-031455), on March 18, 2026, and is solely responsible for the information contained therein.